Your browser doesn't support javascript.
loading
Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma.
Suk, Yujin; Singh, Sheila K.
Afiliação
  • Suk Y; Centre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada; Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
  • Singh SK; Centre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, Canada; Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. Electronic address: ssingh@mcmaster.ca.
Cell Rep Med ; 4(6): 101071, 2023 06 20.
Article em En | MEDLINE | ID: mdl-37343514
ABSTRACT
We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.1.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article